晚期慢性肾病和毛细血管前肺动脉高压患者的肺血管扩张剂--病例系列。

IF 0.8 Q4 RESPIRATORY SYSTEM
Respirology Case Reports Pub Date : 2024-09-19 eCollection Date: 2024-09-01 DOI:10.1002/rcr2.70027
Raul Leguizamon, Ian McLaren, Tara John, Rasha Khan, Alexander Prendergast, Phuuwadith Wattanachayakul, Andrew Geller, John Malin, Simone A Jarret, Kevin Bryan Lo, Jose Manuel Martinez Manzano, Christian Witzke
{"title":"晚期慢性肾病和毛细血管前肺动脉高压患者的肺血管扩张剂--病例系列。","authors":"Raul Leguizamon, Ian McLaren, Tara John, Rasha Khan, Alexander Prendergast, Phuuwadith Wattanachayakul, Andrew Geller, John Malin, Simone A Jarret, Kevin Bryan Lo, Jose Manuel Martinez Manzano, Christian Witzke","doi":"10.1002/rcr2.70027","DOIUrl":null,"url":null,"abstract":"<p><p>Pulmonary hypertension (PH) is a prevalent complication among patients with chronic kidney disease (CKD). In these patients, pulmonary vasodilators may be useful but are underused. We describe a group of patients with precapillary PH and advanced CKD treated with pulmonary vasodilators. This was a case series of patients with CKD stage 4 and 5 and precapillary PH (isolated or combined) based on right heart catheterization (RHC) treated with pulmonary vasodilators from 2018 to 2023. Of 263 patients with isolated precapillary or combined PH and advanced CKD, only 17 (6%) were treated with pulmonary vasodilators; 53% (<i>n</i> = 9) with precapillary PH and 47% (<i>n</i> = 8) with combined PH. Most patients (94%, <i>n</i> = 16) received phosphodiesterase-5 antagonists, while 12% (<i>n</i> = 2) received endothelin receptor antagonists. Adverse clinical outcomes were seen in 35% of patients within a year. The use of pulmonary vasodilator did not prevent adverse outcomes in patients with precapillary PH and advanced CKD.</p>","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411268/pdf/","citationCount":"0","resultStr":"{\"title\":\"Pulmonary vasodilators in patients with advanced chronic kidney disease and pre-capillary pulmonary hypertension-A case series.\",\"authors\":\"Raul Leguizamon, Ian McLaren, Tara John, Rasha Khan, Alexander Prendergast, Phuuwadith Wattanachayakul, Andrew Geller, John Malin, Simone A Jarret, Kevin Bryan Lo, Jose Manuel Martinez Manzano, Christian Witzke\",\"doi\":\"10.1002/rcr2.70027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pulmonary hypertension (PH) is a prevalent complication among patients with chronic kidney disease (CKD). In these patients, pulmonary vasodilators may be useful but are underused. We describe a group of patients with precapillary PH and advanced CKD treated with pulmonary vasodilators. This was a case series of patients with CKD stage 4 and 5 and precapillary PH (isolated or combined) based on right heart catheterization (RHC) treated with pulmonary vasodilators from 2018 to 2023. Of 263 patients with isolated precapillary or combined PH and advanced CKD, only 17 (6%) were treated with pulmonary vasodilators; 53% (<i>n</i> = 9) with precapillary PH and 47% (<i>n</i> = 8) with combined PH. Most patients (94%, <i>n</i> = 16) received phosphodiesterase-5 antagonists, while 12% (<i>n</i> = 2) received endothelin receptor antagonists. Adverse clinical outcomes were seen in 35% of patients within a year. The use of pulmonary vasodilator did not prevent adverse outcomes in patients with precapillary PH and advanced CKD.</p>\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11411268/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.70027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

肺动脉高压(PH)是慢性肾脏病(CKD)患者的一种常见并发症。在这些患者中,肺血管扩张剂可能有用,但使用不足。我们描述了一组使用肺血管扩张剂治疗毛细血管前 PH 和晚期 CKD 患者的病例。这是2018年至2023年期间,根据右心导管检查(RHC)使用肺血管扩张剂治疗的CKD 4期和5期且毛细血管前PH(孤立或合并)患者的病例系列。在 263 名孤立性毛细血管前 PH 或合并 PH 且患有晚期 CKD 的患者中,只有 17 人(6%)接受了肺血管扩张剂治疗;毛细血管前 PH 患者占 53%(n = 9),合并 PH 患者占 47%(n = 8)。大多数患者(94%,n = 16)接受了磷酸二酯酶-5 拮抗剂治疗,12%(n = 2)接受了内皮素受体拮抗剂治疗。35%的患者在一年内出现了不良临床结果。使用肺血管扩张剂并不能防止毛细血管前PH和晚期慢性肾脏病患者出现不良后果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pulmonary vasodilators in patients with advanced chronic kidney disease and pre-capillary pulmonary hypertension-A case series.

Pulmonary hypertension (PH) is a prevalent complication among patients with chronic kidney disease (CKD). In these patients, pulmonary vasodilators may be useful but are underused. We describe a group of patients with precapillary PH and advanced CKD treated with pulmonary vasodilators. This was a case series of patients with CKD stage 4 and 5 and precapillary PH (isolated or combined) based on right heart catheterization (RHC) treated with pulmonary vasodilators from 2018 to 2023. Of 263 patients with isolated precapillary or combined PH and advanced CKD, only 17 (6%) were treated with pulmonary vasodilators; 53% (n = 9) with precapillary PH and 47% (n = 8) with combined PH. Most patients (94%, n = 16) received phosphodiesterase-5 antagonists, while 12% (n = 2) received endothelin receptor antagonists. Adverse clinical outcomes were seen in 35% of patients within a year. The use of pulmonary vasodilator did not prevent adverse outcomes in patients with precapillary PH and advanced CKD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Respirology Case Reports
Respirology Case Reports RESPIRATORY SYSTEM-
CiteScore
1.40
自引率
0.00%
发文量
178
审稿时长
8 weeks
期刊介绍: Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信